Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 11/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.42 |
| ▸ | SDHB | P21912 | 1/20 | 0.38 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | USP1 | O94782 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9940251 | 0.91 | DGAT1 (0.55) | DGAT1P2RX7SERPINE1 | |
| SCHEMBL16660865 | 0.84 | DGAT1 (0.66) | DGAT1 | |
| SCHEMBL29194233 | 0.80 | DRD2 (0.47) | DGAT1P2RX7SDHBNPC1RAB9A | |
| SCHEMBL7469586 | 0.75 | PTGS2 (0.46) | SDHBRAB9ASMN1; SMN2BRD4USP1 | |
| SCHEMBL9940133 | 0.74 | DGAT1 (0.79) | DGAT1 | |
| SCHEMBL20169336 | 0.74 | DGAT1 (0.63) | DGAT1 | |
| SCHEMBL9936473 | 0.73 | DGAT1 (0.65) | DGAT1 | |
| SCHEMBL15282810 | 0.73 | DGAT1 (0.67) | DGAT1 | |
| SCHEMBL20169319 | 0.73 | DGAT1 (0.51) | DGAT1 | |
| SCHEMBL20169345 | 0.73 | DGAT1 (0.53) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975871-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9975871-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9975871-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20160272614-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160272614-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160272614-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-2651915-B1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-25 | — | — | EP | disclosed |
| EP-2651915-B1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-9302996-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-05 | — | — | US | disclosed |
| US-9302996-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-05 | — | — | US | disclosed |
| US-9302996-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-05 | — | — | US | disclosed |
| EP-2651915-A1 | CONTINUOUS ARYCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-20130261128-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-03 | — | — | US | disclosed |
| US-20130261128-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-03 | — | — | US | disclosed |
| US-20130261128-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-03 | — | — | US | disclosed |
| WO-2012081736-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012081736-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261128-A1 | CONTINUOUS ARYCYCLIC COMPOUND | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885P2RX7 4489/4885SDHB 3586/4885 |
| US-20160272614-A1 | CONTINUOUS ARYCYCLIC COMPOUND | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885P2RX7 4489/4885SDHB 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.